{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:08Z","timestamp":1785283208535,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T00:00:00Z","timestamp":1729123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00210-024-03536-3","type":"journal-article","created":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T12:03:10Z","timestamp":1729166590000},"page":"4123-4148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["RETRACTED ARTICLE: A promise of nose to brain delivery of bevacizumab intranasal sol\u2013gel formulation substantiated in rat C6 glioma model"],"prefix":"10.1007","volume":"398","author":[{"given":"Siddhesh","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajakta","family":"Thorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Majumdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,17]]},"reference":[{"issue":"5","key":"3536_CR1","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/01.iae.0000225354.92444.7a","volume":"26","author":"SJ Bakri","year":"2006","unstructured":"Bakri SJ, Snyder MR, Pulido JS, Mccannel CA, Weiss WT, Singh RJ (2006) Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing. Retina 26(5):519\u2013522","journal-title":"Retina"},{"issue":"2","key":"3536_CR2","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1634\/theoncologist.2014-0330","volume":"20","author":"AA Brandes","year":"2015","unstructured":"Brandes AA, Bartolotti M, Tosoni A, Poggi R, Franceschi E (2015) Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist 20(2):166\u2013175. https:\/\/doi.org\/10.1634\/theoncologist.2014-0330","journal-title":"Oncologist"},{"key":"3536_CR3","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ejpb.2016.08.020","volume":"108","author":"K Bukara","year":"2016","unstructured":"Bukara K, Schueller L, Rosier J, Martens MA, Daems T, Verheyden L, Eelen S, Van Speybroeck M, Libanati C, Martens JA, Van Den Mooter G, Fr\u00e9rart F, Jolling K, De Gieter M, Bugarski B, Kiekens F (2016) Ordered mesoporous silica to enhance the bioavailability of poorly water-soluble drugs: proof of concept in man. Eur J Pharm Biopharm 108:220\u2013225. https:\/\/doi.org\/10.1016\/j.ejpb.2016.08.020","journal-title":"Eur J Pharm Biopharm"},{"key":"3536_CR4","unstructured":"Chan W, Allen J, Dorovini-Zis K, Grumet M (1996) Article in cancer research. http:\/\/cancerres.aacrjournals.org\/content\/56\/1\/182.\u00a0Accessed\u00a028 Feb 2024"},{"issue":"9","key":"3536_CR5","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/nrd2614","volume":"7","author":"ME Davis","year":"2008","unstructured":"Davis ME, Chen Z, Shin DM (2008) Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7(9):771\u2013782. https:\/\/doi.org\/10.1038\/nrd2614","journal-title":"Nat Rev Drug Discov"},{"issue":"20","key":"3536_CR6","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.2217\/nnm-2021-0169","volume":"16","author":"A De Cristo Soares Alves","year":"2021","unstructured":"De Cristo Soares Alves A, Lavayen V, De Fraga Dias A, Bruinsmann FA, Scholl JN, C\u00e9 R, Visioli F, Oliveira Battastini AM, Stanis\u00e7uaski Guterres S, Figueir\u00f3 F, Raffin Pohlmann A (2021) EGFRvIII peptide nanocapsules and bevacizumab nanocapsules: a nose-to-brain multitarget approach against glioblastoma. Nanomedicine 16(20):1775\u20131790. https:\/\/doi.org\/10.2217\/nnm-2021-0169","journal-title":"Nanomedicine"},{"issue":"9","key":"3536_CR7","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.3390\/ani11092662","volume":"11","author":"B Ferry","year":"2021","unstructured":"Ferry B, Gervasoni D (2021) Improving stereotaxic neurosurgery techniques and procedures greatly reduces the number of rats used per experimental group\u2014a practice report. Animals 11(9):2662. https:\/\/doi.org\/10.3390\/ani11092662","journal-title":"Animals"},{"key":"3536_CR8","doi-asserted-by":"publisher","unstructured":"Fonseca-Santos B, Chorilli M, Palmira Daflon Gremi\u00e3o M (2015) Nanotechnology-based drug delivery systems for the treatment of Alzheimer\u2019s disease. Int J Nanomedicine 4981. https:\/\/doi.org\/10.2147\/IJN.S87148","DOI":"10.2147\/IJN.S87148"},{"key":"3536_CR9","doi-asserted-by":"publisher","first-page":"e880","DOI":"10.3791\/880","volume":"20","author":"BM Geiger","year":"2008","unstructured":"Geiger BM, Frank LE, Caldera-Siu AD, Pothos EN (2008) Survivable stereotaxic surgery in rodents. J Visualized Exp 20:e880. https:\/\/doi.org\/10.3791\/880","journal-title":"J Visualized Exp"},{"issue":"1","key":"3536_CR10","doi-asserted-by":"publisher","first-page":"17556","DOI":"10.1038\/s41598-017-17752-w","volume":"7","author":"A Gieryng","year":"2017","unstructured":"Gieryng A, Pszczolkowska D, Bocian K, Dabrowski M, Rajan WD, Kloss M, Mieczkowski J, Kaminska B (2017) Immune microenvironment of experimental rat C6 gliomas resembles human glioblastomas. Sci Rep 7(1):17556. https:\/\/doi.org\/10.1038\/s41598-017-17752-w","journal-title":"Sci Rep"},{"issue":"1","key":"3536_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1091\/mbc.4.1.121","volume":"4","author":"CK Goldman","year":"1993","unstructured":"Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4(1):121\u2013133. https:\/\/doi.org\/10.1091\/mbc.4.1.121","journal-title":"Mol Biol Cell"},{"key":"3536_CR12","unstructured":"Guidance for Industry Q8(R2) Pharmaceutical Development (2009) http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm"},{"issue":"31","key":"3536_CR13","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O\u2019Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil\u2013based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794\u20137803. https:\/\/doi.org\/10.1200\/JCO.2005.04.937","journal-title":"J Clin Oncol"},{"issue":"1","key":"3536_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.22034\/APJCP.2017.18.1.3","volume":"18","author":"F Hanif","year":"2017","unstructured":"Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU (2017) Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev 18(1):3\u20139. https:\/\/doi.org\/10.22034\/APJCP.2017.18.1.3. (Asian Pacific Organization for Cancer Prevention)","journal-title":"Asian Pac J Cancer Prev"},{"key":"3536_CR15","doi-asserted-by":"publisher","first-page":"100048","DOI":"10.1016\/j.onano.2022.100048","volume":"7","author":"Y Herdiana","year":"2022","unstructured":"Herdiana Y, Wathoni N, Shamsuddin S, Muchtaridi M (2022) Scale-up polymeric-based nanoparticles drug delivery systems: development and challenges. OpenNano 7:100048. https:\/\/doi.org\/10.1016\/j.onano.2022.100048","journal-title":"OpenNano"},{"key":"3536_CR16","doi-asserted-by":"publisher","unstructured":"Intranasal delivery of 125I-NGF to the brain via the olfactory route (1994) Neurobiol Aging 15, S137\u2013S138. https:\/\/doi.org\/10.1016\/0197-4580(94)93019-8","DOI":"10.1016\/0197-4580(94)93019-8"},{"issue":"2","key":"3536_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1215\/15228517-2008-077","volume":"11","author":"K Jahnke","year":"2009","unstructured":"Jahnke K, Muldoon LL, Varallyay CG, Lewin SJ, Kraemer DF, Neuwelt EA (2009) Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model. Neuro Oncol 11(2):142\u2013150. https:\/\/doi.org\/10.1215\/15228517-2008-077","journal-title":"Neuro Oncol"},{"issue":"4","key":"3536_CR18","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3390\/nano10040815","volume":"10","author":"P Joyce","year":"2020","unstructured":"Joyce P, Ulmefors H, Maghrebi S, Subramaniam S, Wignall A, J\u00f5emetsa S, H\u00f6\u00f6k F, Prestidge CA (2020) Enhancing the cellular uptake and antibacterial activity of rifampicin through encapsulation in mesoporous silica nanoparticles. Nanomaterials 10(4):815. https:\/\/doi.org\/10.3390\/nano10040815","journal-title":"Nanomaterials"},{"key":"3536_CR19","doi-asserted-by":"publisher","unstructured":"Karpov AA, Vaulina DD, Smirnov SS, Moiseeva OM, Galagudza MM (2022) Rodent models of pulmonary embolism and chronic thromboembolic pulmonary hypertension. Heliyon 8(3). https:\/\/doi.org\/10.1016\/j.heliyon.2022.e09014 (Elsevier Ltd)","DOI":"10.1016\/j.heliyon.2022.e09014"},{"issue":"4","key":"3536_CR20","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/00005537-200004000-00021","volume":"110","author":"T Keck","year":"2000","unstructured":"Keck T, Leiacker R, Riechelmann H, Rettinger G (2000) Temperature profile in the nasal cavity. Laryngoscope 110(4):651\u2013654. https:\/\/doi.org\/10.1097\/00005537-200004000-00021","journal-title":"Laryngoscope"},{"issue":"6","key":"3536_CR21","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/eye.2015.28","volume":"29","author":"H Khalili","year":"2015","unstructured":"Khalili H, Sharma G, Froome A, Khaw PT, Brocchini S (2015) Storage stability of bevacizumab in polycarbonate and polypropylene syringes. Eye 29(6):820\u2013827. https:\/\/doi.org\/10.1038\/eye.2015.28","journal-title":"Eye"},{"issue":"3","key":"3536_CR22","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3109\/10611860903386938","volume":"18","author":"S Khan","year":"2010","unstructured":"Khan S, Patil K, Bobade N, Yeole P, Gaikwad R (2010) Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target 18(3):223\u2013234. https:\/\/doi.org\/10.3109\/10611860903386938","journal-title":"J Drug Target"},{"issue":"3","key":"3536_CR23","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1586\/erm.13.15","volume":"13","author":"TH Kim","year":"2013","unstructured":"Kim TH, Lee S, Chen X (2013) Nanotheranostics for personalized medicine. Expert Rev Mol Diagn 13(3):257\u2013269. https:\/\/doi.org\/10.1586\/erm.13.15","journal-title":"Expert Rev Mol Diagn"},{"issue":"2","key":"3536_CR24","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/pharmaceutics13020184","volume":"13","author":"M-K Kim","year":"2021","unstructured":"Kim M-K, Ki D-H, Na Y-G, Lee H-S, Baek J-S, Lee J-Y, Lee H-K, Cho C-W (2021) Optimization of mesoporous silica nanoparticles through statistical design of experiment and the application for the anticancer drug. Pharmaceutics 13(2):184. https:\/\/doi.org\/10.3390\/pharmaceutics13020184","journal-title":"Pharmaceutics"},{"issue":"9","key":"3536_CR25","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3109\/1061186X.2015.1020809","volume":"23","author":"AD Kulkarni","year":"2015","unstructured":"Kulkarni AD, Vanjari YH, Sancheti KH, Belgamwar VS, Surana SJ, Pardeshi CV (2015) Nanotechnology-mediated nose to brain drug delivery for Parkinson\u2019s disease: a mini review. J Drug Target 23(9):775\u2013788. https:\/\/doi.org\/10.3109\/1061186X.2015.1020809","journal-title":"J Drug Target"},{"issue":"2","key":"3536_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.18383\/j.tom.2018.00012","volume":"4","author":"TNT Le","year":"2018","unstructured":"Le TNT, Lim H, Hamilton AM, Parkins KM, Chen Y, Scholl TJ, Ronald JA (2018) Characterization of an orthotopic rat model of glioblastoma using multiparametric magnetic resonance imaging and bioluminescence imaging. Tomography (Ann Arbor, Mich) 4(2):55\u201365. https:\/\/doi.org\/10.18383\/j.tom.2018.00012","journal-title":"Tomography (Ann Arbor, Mich)"},{"issue":"3","key":"3536_CR27","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","volume":"3","author":"SY Lee","year":"2016","unstructured":"Lee SY (2016) Temozolomide resistance in glioblastoma multiforme. Genes Dis 3(3):198\u2013210. https:\/\/doi.org\/10.1016\/j.gendis.2016.04.007. (Chongqing yi ke da xue, di 2 lin chuang xue yuan Bing du xing gan yan yan jiu suo)","journal-title":"Genes Dis"},{"issue":"12","key":"3536_CR28","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/pharmaceutics13122049","volume":"13","author":"D Lee","year":"2021","unstructured":"Lee D, Minko T (2021) Nanotherapeutics for nose-to-brain drug delivery: an approach to bypass the blood brain barrier. Pharmaceutics 13(12):2049. https:\/\/doi.org\/10.3390\/pharmaceutics13122049. (MDPI)","journal-title":"Pharmaceutics"},{"issue":"3","key":"3536_CR29","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s13346-020-00853-x","volume":"11","author":"TR Meola","year":"2021","unstructured":"Meola TR, Abuhelwa AY, Joyce P, Clifton P, Prestidge CA (2021) A safety, tolerability, and pharmacokinetic study of a novel simvastatin silica-lipid hybrid formulation in healthy male participants. Drug Deliv Transl Res 11(3):1261\u20131272. https:\/\/doi.org\/10.1007\/s13346-020-00853-x","journal-title":"Drug Deliv Transl Res"},{"issue":"6","key":"3536_CR30","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.tips.2010.03.003","volume":"31","author":"DS Miller","year":"2010","unstructured":"Miller DS (2010) Regulation of P-glycoprotein and other ABC drug transporters at the blood\u2013brain barrier. Trends Pharmacol Sci 31(6):246\u2013254. https:\/\/doi.org\/10.1016\/j.tips.2010.03.003","journal-title":"Trends Pharmacol Sci"},{"issue":"Supplement_5","key":"3536_CR31","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","volume":"21","author":"QT Ostrom","year":"2019","unstructured":"Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS (2019) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012\u20132016. Neuro-Oncology 21(Supplement_5):v1\u2013v100. https:\/\/doi.org\/10.1093\/neuonc\/noz150","journal-title":"Neuro-Oncology"},{"key":"3536_CR32","doi-asserted-by":"publisher","unstructured":"Pandey V, Gadeval A, Asati S, Jain P, Jain N, Roy RK, Tekade M, Soni V, Tekade RK (2020) Formulation strategies for nose-to-brain delivery of therapeutic molecules. In: Drug Delivery Systems. Elsevier, pp 291\u2013332. https:\/\/doi.org\/10.1016\/B978-0-12-814487-9.00007-7","DOI":"10.1016\/B978-0-12-814487-9.00007-7"},{"issue":"7","key":"3536_CR33","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/21691401.2016.1243545","volume":"45","author":"J Pandit","year":"2017","unstructured":"Pandit J, Sultana Y, Aqil M (2017) Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation. Artif Cells Nanomedicine Biotechnol 45(7):1397\u20131407. https:\/\/doi.org\/10.1080\/21691401.2016.1243545","journal-title":"Artif Cells Nanomedicine Biotechnol"},{"issue":"12","key":"3536_CR34","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nnano.2007.387","volume":"2","author":"D Peer","year":"2007","unstructured":"Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R (2007) Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2(12):751\u2013760. https:\/\/doi.org\/10.1038\/nnano.2007.387","journal-title":"Nat Nanotechnol"},{"issue":"2","key":"3536_CR35","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/pharmaceutics13020258","volume":"13","author":"E Peira","year":"2021","unstructured":"Peira E, Chindamo G, Chirio D, Sapino S, Oliaro-Bosso S, Rebba E, Ivanchenko P, Gallarate M (2021) Assessment of in-situ gelling microemulsion systems upon temperature and dilution condition for corneal delivery of bevacizumab. Pharmaceutics 13(2):258. https:\/\/doi.org\/10.3390\/pharmaceutics13020258","journal-title":"Pharmaceutics"},{"key":"3536_CR36","doi-asserted-by":"publisher","unstructured":"Rahmathulla G, Hovey, Hashemi-Sardraei, Ahluwalia (2013) Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges. OncoTargets Ther 371. https:\/\/doi.org\/10.2147\/OTT.S38628","DOI":"10.2147\/OTT.S38628"},{"key":"3536_CR37","doi-asserted-by":"crossref","unstructured":"Rana MA, Khan RA, Nasiruddin M, Khan AA (2016). Amelioration of cisplatin-induced nephrotoxicity by ethanolic extract of Bauhinia purpurea: an in vivo study in rats. Saudi J Kidney Dis Transpl 27(1). http:\/\/www.sjkdt.org.\u00a0\u00a0Accessed\u00a06 Mar 2024","DOI":"10.4103\/1319-2442.174068"},{"issue":"4","key":"3536_CR38","doi-asserted-by":"publisher","first-page":"414","DOI":"10.6004\/jnccn.2011.0038","volume":"9","author":"DA Reardon","year":"2011","unstructured":"Reardon DA, Turner S, Peters KB, Desjardins A, Gururangan S, Sampson JH, McLendon RE, Herndon JE, Jones LW, Kirkpatrick JP, Friedman AH, Vredenburgh JJ, Bigner DD, Friedman HS (2011) A review of VEGF\/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw 9(4):414\u2013427. https:\/\/doi.org\/10.6004\/jnccn.2011.0038","journal-title":"J Natl Compr Canc Netw"},{"issue":"14","key":"3536_CR39","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.3390\/molecules26144247","volume":"26","author":"F Rizzi","year":"2021","unstructured":"Rizzi F, Castaldo R, Latronico T, Lasala P, Gentile G, Lavorgna M, Striccoli M, Agostiano A, Comparelli R, Depalo N, Curri ML, Fanizza E (2021) High surface area mesoporous silica nanoparticles with tunable size in the sub-micrometer regime: insights on the size and porosity control mechanisms. Molecules 26(14):4247. https:\/\/doi.org\/10.3390\/molecules26144247","journal-title":"Molecules"},{"issue":"1\u20132","key":"3536_CR40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijpharm.2018.10.029","volume":"553","author":"J Rohrer","year":"2018","unstructured":"Rohrer J, Lupo N, Bernkop-Schn\u00fcrch A (2018) Advanced formulations for intranasal delivery of biologics. Int J Pharm 553(1\u20132):8\u201320. https:\/\/doi.org\/10.1016\/j.ijpharm.2018.10.029","journal-title":"Int J Pharm"},{"issue":"12","key":"3536_CR41","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.3390\/ijms22126514","volume":"22","author":"S Rosi\u0144ska","year":"2021","unstructured":"Rosi\u0144ska S, Gavard J (2021) Tumor vessels fuel the fire in glioblastoma. Int J Mol Sci 22(12):6514. https:\/\/doi.org\/10.3390\/ijms22126514","journal-title":"Int J Mol Sci"},{"key":"3536_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijpharm.2019.02.026","volume":"561","author":"L Salade","year":"2019","unstructured":"Salade L, Wauthoz N, Goole J, Amighi K (2019) How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods. Int J Pharm 561:47\u201365. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.02.026","journal-title":"Int J Pharm"},{"issue":"10","key":"3536_CR43","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1016\/j.bmc.2017.11.001","volume":"26","author":"E Samaridou","year":"2018","unstructured":"Samaridou E, Alonso MJ (2018) Nose-to-brain peptide delivery \u2013 the potential of nanotechnology. Bioorg Med Chem 26(10):2888\u20132905. https:\/\/doi.org\/10.1016\/j.bmc.2017.11.001","journal-title":"Bioorg Med Chem"},{"key":"3536_CR44","doi-asserted-by":"publisher","unstructured":"Selvaraj K, Gowthamarajan K, Karri VVSR (2017) Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting. Artif Cells Nanomedicine Biotechnol 1\u20138. https:\/\/doi.org\/10.1080\/21691401.2017.1420073","DOI":"10.1080\/21691401.2017.1420073"},{"issue":"4","key":"3536_CR45","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3171\/jns.2007.106.4.601","volume":"106","author":"TJ Semrad","year":"2007","unstructured":"Semrad TJ, O\u2019Donnell R, Wun T, Chew H, Harvey D, Zhou H, White RH (2007) Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 106(4):601\u2013608. https:\/\/doi.org\/10.3171\/jns.2007.106.4.601","journal-title":"J Neurosurg"},{"issue":"1","key":"3536_CR46","doi-asserted-by":"publisher","first-page":"vdad009","DOI":"10.1093\/noajnl\/vdad009","volume":"5","author":"P Sharma","year":"2023","unstructured":"Sharma P, Aaroe A, Liang J, Puduvalli VK (2023) Tumor microenvironment in glioblastoma: current and emerging concepts. Neuro-Oncol Adv 5(1):vdad009. https:\/\/doi.org\/10.1093\/noajnl\/vdad009","journal-title":"Neuro-Oncol Adv"},{"issue":"4","key":"3536_CR47","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1021\/acsami.8b15390","volume":"11","author":"H Shi","year":"2019","unstructured":"Shi H, Liu S, Cheng J, Yuan S, Yang Y, Fang T, Cao K, Wei K, Zhang Q, Liu Y (2019) Charge-selective delivery of proteins using mesoporous silica nanoparticles fused with lipid bilayers. ACS Appl Mater Interfaces 11(4):3645\u20133653. https:\/\/doi.org\/10.1021\/acsami.8b15390","journal-title":"ACS Appl Mater Interfaces"},{"issue":"44","key":"3536_CR48","doi-asserted-by":"publisher","first-page":"17284","DOI":"10.1039\/C9NJ03001H","volume":"43","author":"F Song","year":"2019","unstructured":"Song F, Li Y, Wang S, Zhang L, Chen Q (2019) Multifunctional dual-mesoporous silica nanoparticles loaded with a protein and dual antitumor drugs as a targeted delivery system. New J Chem 43(44):17284\u201317297. https:\/\/doi.org\/10.1039\/C9NJ03001H","journal-title":"New J Chem"},{"key":"3536_CR49","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jconrel.2019.07.033","volume":"309","author":"F Sousa","year":"2019","unstructured":"Sousa F, Dhaliwal HK, Gattacceca F, Sarmento B, Amiji MM (2019) Enhanced anti-angiogenic effects of bevacizumab in glioblastoma treatment upon intranasal administration in polymeric nanoparticles. J Control Release 309:37\u201347. https:\/\/doi.org\/10.1016\/j.jconrel.2019.07.033","journal-title":"J Control Release"},{"issue":"1","key":"3536_CR50","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/0021-9797(68)90272-5","volume":"26","author":"W St\u00f6ber","year":"1968","unstructured":"St\u00f6ber W, Fink A, Bohn E (1968) Controlled growth of monodisperse silica spheres in the micron size range. J Colloid Interface Sci 26(1):62\u201369. https:\/\/doi.org\/10.1016\/0021-9797(68)90272-5","journal-title":"J Colloid Interface Sci"},{"key":"3536_CR51","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.2147\/IJN.S195504","volume":"14","author":"J-G Sun","year":"2019","unstructured":"Sun J-G, Jiang Q, Zhang X-P, Shan K, Liu B-H, Zhao C, Yan B (2019) <p>Mesoporous silica nanoparticles as a delivery system for improving antiangiogenic therapy<\/p>. Int J Nanomed 14:1489\u20131501. https:\/\/doi.org\/10.2147\/IJN.S195504","journal-title":"Int J Nanomed"},{"issue":"9","key":"3536_CR52","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1016\/j.xphs.2016.03.035","volume":"105","author":"Y Wang","year":"2016","unstructured":"Wang Y, Li M, Qian S, Zhang Q, Zhou L, Zuo Z, Lee B, Toh M, Ho T (2016) Zolpidem mucoadhesive formulations for intranasal delivery: characterization, in vitro permeability, pharmacokinetics, and nasal ciliotoxicity in rats. J Pharm Sci 105(9):2840\u20132847. https:\/\/doi.org\/10.1016\/j.xphs.2016.03.035","journal-title":"J Pharm Sci"},{"key":"3536_CR53","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijbiomac.2013.05.034","volume":"60","author":"X Xu","year":"2013","unstructured":"Xu X, Weng Y, Xu L, Chen H (2013) Sustained release of Avastin\u00ae from polysaccharides cross-linked hydrogels for ocular drug delivery. Int J Biol Macromol 60:272\u2013276. https:\/\/doi.org\/10.1016\/j.ijbiomac.2013.05.034","journal-title":"Int J Biol Macromol"},{"key":"3536_CR54","doi-asserted-by":"publisher","first-page":"290","DOI":"10.3389\/fchem.2019.00290","volume":"7","author":"C Xu","year":"2019","unstructured":"Xu C, Lei C, Yu C (2019) Mesoporous silica nanoparticles for protein protection and delivery. Front Chem 7:290. https:\/\/doi.org\/10.3389\/fchem.2019.00290","journal-title":"Front Chem"},{"issue":"5","key":"3536_CR55","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1021\/am405633r","volume":"6","author":"H Yamada","year":"2014","unstructured":"Yamada H, Urata C, Higashitamori S, Aoyama Y, Yamauchi Y, Kuroda K (2014) Critical roles of cationic surfactants in the preparation of colloidal mesostructured silica nanoparticles: control of mesostructure, particle size, and dispersion. ACS Appl Mater Interfaces 6(5):3491\u20133500. https:\/\/doi.org\/10.1021\/am405633r","journal-title":"ACS Appl Mater Interfaces"},{"key":"3536_CR56","doi-asserted-by":"publisher","first-page":"829796","DOI":"10.3389\/fphar.2022.829796","volume":"13","author":"C Zhang","year":"2022","unstructured":"Zhang C, Xie H, Zhang Z, Wen B, Cao H, Bai Y, Che Q, Guo J, Su Z (2022) Applications and biocompatibility of mesoporous silica nanocarriers in the field of medicine. Front Pharmacol 13:829796. https:\/\/doi.org\/10.3389\/fphar.2022.829796. (Frontiers Media S.A)","journal-title":"Front Pharmacol"},{"key":"3536_CR57","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.actbio.2017.09.009","volume":"63","author":"R Zhu","year":"2017","unstructured":"Zhu R, Wang Z, Liang P, He X, Zhuang X, Huang R, Wang M, Wang Q, Qian Y, Wang S (2017) Efficient VEGF targeting delivery of DOX using bevacizumab conjugated SiO2@LDH for anti-neuroblastoma therapy. Acta Biomater 63:163\u2013180. https:\/\/doi.org\/10.1016\/j.actbio.2017.09.009","journal-title":"Acta Biomater"}],"updated-by":[{"DOI":"10.1007\/s00210-025-04177-w","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000}},{"DOI":"10.1007\/s00210-025-04177-w","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"record-id":"71831"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03536-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03536-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03536-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T11:39:44Z","timestamp":1745235584000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03536-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,17]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3536"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03536-3","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,17]]},"assertion":[{"value":"16 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00210-025-04177-w","URL":"https:\/\/doi.org\/10.1007\/s00210-025-04177-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Rats were used as test subjects for the in vivo animal investigations, which were approved by the Institutional Animal Ethics Committee (IAEC) (Protocol no. BCP\/2021\u201301\/03, BCP\/2022\u201302\/02, and BCP\/2023\u201301\/02). There were no human studies conducted as part of the research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}